This Little-Known Stock Has Surged 550% in the Past Year
This Little-Known Stock Has Surged 550% in the Past Year.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
SELLAS Life Sciences (SLS) has surged 550% in the past year, driven by technical momentum and speculative trading.
SLS currently has no revenue, with all products in development or clinical trials, making the stock highly speculative.
Technical indicators are overwhelmingly bullish, but high short interest highlights significant risk.
Sentiment is mixed: Barchart and Value Line are bullish, while Morningstar and Seeking Alpha rate SLS as "Hold" or suggest it is overvalued.
Valued at $2.95 billion, SELLAS Life Sciences (SLS) focuses on the development of novel cancer immunotherapies for various cancer indications.
I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction, a Weighted Alpha above 50+, and a 60-month beta above 1.5. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. SLS checks those boxes. The Trend Seeker issued a new "Buy" signal on May 13. Since then, the stock has gained 119.20%.
Sentiment Could Be Turning Sour on Nvidia. Here's Where 1 Analyst Thinks NVDA Stock Is Headed Next.
Google Just Launched 2 New AI Models. What That Means for GOOGL Stock.
Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
The stock recently traded at $14.16 with a 50-day moving average of $7.98.
SLS has made 8 new highs and gained 74% over the past month.
This company currently has no revenue and is in the drug development and trial stages.
The Wall Street analyst followed by Barchart gives the stock 1 "Strong Buy" opinion.
Value Line rates the stock "Highest" but that is based solely on price performance.
Morningstar thinks the stock is 39% overvalued with a fair value of $10.95.
36,940 investors are following the stock on Seeking Alpha, which rates it a "Hold." Their analysts note a high valuation and a lack of revenue and earnings.
Short interest is a high 32.22% of the float with 9.25 days to cover the float.
